Provided by Tiger Fintech (Singapore) Pte. Ltd.

Akebia Therapeutics

2.26
+0.570033.73%
Post-market: 2.22-0.0400-1.77%19:59 EDT
Volume:13.25M
Turnover:28.51M
Market Cap:533.36M
PE:-9.89
High:2.29
Open:1.77
Low:1.76
Close:1.69
Loading ...

Akebia Therapeutics (NASDAQ:AKBA investor five-year losses grow to 80% as the stock sheds US$55m this past week

Simply Wall St.
·
27 Feb

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
05 Feb

Akebia Therapeutics Price Target Maintained With a $7.50/Share by HC Wainwright & Co.

Dow Jones
·
24 Jan

Akebia Therapeutics Price Target Maintained With a $7.50/Share by HC Wainwright & Co.

Dow Jones
·
15 Jan

Akebia Therapeutics: Strong Market Position and Growth Potential Justifies Buy Rating

TIPRANKS
·
15 Jan

Akebia announces ‘multiple positive business updates’

TipRanks
·
14 Jan

Akebia Therapeutics Inc: Vafseo Tablets NOW Shipping in U.S.

THOMSON REUTERS
·
13 Jan

Akebia Therapeutics Announces Multiple Positive Business Updates

PR Newswire
·
13 Jan

New Strong Sell Stocks for January 3rd

Zacks
·
03 Jan

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire
·
03 Jan

High Growth Tech Stocks To Watch In December 2024

Simply Wall St.
·
21 Dec 2024

New Strong Sell Stocks for December 5th

Zacks
·
05 Dec 2024

BRIEF-U.S. Renal Care Enrolls First Patients In The Voice Collaborative Clinical Trial Of Vafseo® (Vadadustat) For CKD Patients On Dialysis

Reuters
·
03 Dec 2024

Akebia: U.S. Renal Care enrolls first patient in its VOICE collaborative trial

TIPRANKS
·
03 Dec 2024

Akebia Therapeutics Inc - Vafseo Expected to Be Available in U.S. in January 2025

THOMSON REUTERS
·
03 Dec 2024

U.S. Renal Care Enrolled First Patients in the Voice Collaborative Clinical Trial of Vafseo® (Vadadustat) for Ckd Patients on Dialysis

THOMSON REUTERS
·
03 Dec 2024